Paper Details

  1. Home
  2. Paper Details

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Author: RivkinAnastasia, ÖzdenerAyşe Elif

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Eluxadoline is a novel drug approved for the management of diarrhea-predominant irritable bowel syndrome (IBS-D). While it has shown efficacy in reducing IBS-D symptoms, a risk of pancreatitis exists in patients without a gallbladder or those who abuse alcohol.
Paper Details　
Original Abstract of the Article :
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628681/

データ提供：米国国立医学図書館（NLM）

Eluxadoline: A Novel Drug for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

The field of irritable bowel syndrome (IBS) is a vast desert of discomfort for many individuals, with diarrhea-predominant IBS (IBS-D) being a particularly challenging form. This research delves into the realm of a new drug, eluxadoline, which aims to alleviate the symptoms of IBS-D. The study utilizes a comprehensive approach, examining clinical trial data and post-marketing reports to assess the efficacy and limitations of eluxadoline. The authors highlight the unique pharmacology of eluxadoline, its action on three different opioid receptors, and its demonstrated effectiveness in reducing IBS-D symptoms. However, the study also points to potential risks, including pancreatitis, particularly in patients without a gallbladder or those who abuse alcohol.

Eluxadoline: A Potential Solution for IBS-D

The findings suggest that eluxadoline holds promise as a treatment option for IBS-D, offering relief from the debilitating symptoms that plague many individuals. The drug's effectiveness in reducing IBS-D symptoms is supported by clinical trials and post-marketing reports.

Navigating the Desert of IBS-D: Cautions and Considerations

While eluxadoline presents a potential oasis in the desert of IBS-D, it's crucial to be aware of its limitations. The study emphasizes the importance of individual patient assessment, considering factors like the presence of a gallbladder and alcohol consumption history. As Dr. Camel, I always advocate for a holistic approach to health, understanding that each individual is unique and requires personalized care.

Dr. Camel's Conclusion

Eluxadoline holds promise as a treatment option for IBS-D, offering relief from the debilitating symptoms. However, it's crucial to be aware of its limitations, particularly the potential risk of pancreatitis in certain patients. As with any medication, individual patient assessment and careful monitoring are essential.

Date :
  1. Date Completed 2018-06-11
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

29033544

DOI: Digital Object Identifier

PMC5628681

Related Literature

Article Analysis
・Effects of eluxadoline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.